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secondary hyperparathyroidism.
Background. Impairment of growth in children with chronic
renal failure may be due, in part to the insensitivity to the ac-
tions of growth hormone by insulin-like growth factor-I (IGF-I)
because of accumulations of IGF binding proteins. There are a
few studies describing the changes that occur in the growth plate
in renal failure. None of these studies has simultaneously com-
pared the modifications in the expression of selected markers
of endochondral bone formation in renal failure with mild or
advanced secondary hyperparathyroidism.
Methods. Forty-six rats that underwent 5/6 nephrectomy (Nx)
were fed either standard rodent diet (Nx-control) or high phos-
phorus diet to induce advanced secondary hyperparathyroidism
(Nx-phosphorus) for 4 weeks. Sections of the tibia were ob-
tained for growth plate histomorphometry, immunohistochem-
istry studies, and in situ hybridization experiments for selected
markers of endochondral bone formation.
Results. Weight gain, gain in length, and tibial length were less
in Nx animals. Serum parathyroid hormone (PTH) and phos-
phorus levels were higher and serum calcium levels were lower
in the Nx-phosphorus group. The width of the growth plate was
much shorter in the Nx-phosphorus group due to a decrease
in both proliferative and hypertrophic zones. IGF-I protein
and IGF binding protein-3 staining were diminished in both
Nx groups without changes in the IGF-I receptor expression;
the decline in IGF-I protein expression was much lower in the
Nx-phosphorus group. PTH/PTH receptor protein (PTHrP) re-
ceptor mRNA transcripts decline and tartrate-resistant acid
phosphastase (TRAP) staining increased only in the Nx-
phosphorus group.
Conclusion. The growth impairment in renal failure may be
worsened by the severity of secondary hyperparathyroidism.
The growth plate cartilage is important in bone elonga-
tion and longitudinal growth. Bone elongation is achieved
by the complex interplay of chondrocyte proliferation,
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matrix synthesis, chondrocyte maturation and hypertro-
phy, matrix degradation, angiogenesis, and mineraliza-
tion. In the presence of renal failure, abnormalities in
the histology of the growth plate cartilage have been re-
ported in animals, and these alterations may contribute to
the impairment of linear growth reported in young ure-
mic children. Cobo et al [1] have shown that the width
of the growth plate was increased in nephrectomized
rats compared to animals with normal renal function due
to the widening of the hypertrophic zone. Furthermore,
there was low chondrocyte turnover and impairment of
cartilage resorption in the chondro-osseous junction [1];
however, the degree of secondary hyperparathyroidism
in these experiments were unknown. In contrast, we have
shown that the growth plate width was decreased and the
microarchitecture of the growth plate was disorganized
in rats with renal failure and severe secondary hyper-
parathyroidism accompanied by a decline in the expres-
sion of the parathyroid hormone/parathyroid hormone
receptor protein (PTH/PTHrP) receptor mRNA in the
proliferating and maturing chondrocytes [2]. Similar find-
ings were reported by Uren˜a et al [3] in rats that were
given high phosphorus diet to induce severe secondary
hyperparathyroidism. Currently, there are no concurrent
studies available that compare changes in the growth
plate cartilage in renal failure with mild or advanced
secondary hyperparathyroidism. Our previous study was
done mainly to evaluate the effects of growth hormone
and calcitriol on the growth plate in renal failure, but the
experiments were not done simultaneously [2]. Although
serum insulin-like growth factor-I (IGF-I) levels have
been reported to be within normal limits in rats with renal
failure, there was a significant decline in the expression
of IGF-I mRNA, growth hormone receptor transcripts,
defective mineralization, and alterations in collagen
metabolism [4–6]. As in previous reports, serum PTH lev-
els were not obtained in these studies so the severity of
secondary hyperparathyroidism cannot be evaluated.
The current set of experiments was performed to
compare the effects of the varying degrees of secondary
hyperparathyroidism on chondrocyte proliferation,
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chondrocyte hypertrophy, matrix degradation, and
initiation of mineralization in young rats with renal
failure.
METHODS
Forty-six male weanling Sprague-Dawley rats (Harlan
Laboratories, Madison, WI, USA) with a mean weight
of 57 ± 3 g were housed in individual cages at constant
temperature with a 12-hour light and 12-hour dark cy-
cle. The animals had free access to drinking water and
standard rodent diet containing 23.4% protein, 0.6% cal-
cium, and 0.6% phosphorus (Purina Mills, Indianapolis,
IN, USA). After 24 hours of acclimatization, 16 rats un-
derwent the first stage of a two-stage 5/6 nephrectomy
(Nx), and 30 rats underwent sham nephrectomy (intact)
using surgical procedures described elsewhere [2]. The
second-stage nephrectomy was completed 7 days later.
The 4-week study period began 24 hours after comple-
tion of the second surgery. All procedures were reviewed
and approved by the Research Animal Resource Center
at the University of Wisconsin, Madison, Wisconsin.
Measurements of body weight and body length were
obtained weekly. Fifteen sham-nephrectomized animals
(intact-control), and six nephrectomized animals (Nx-
control) continued to ingest standard rodent diet. To in-
duce advanced secondary hyperparathyroidism, ten Nx
rats were given high phosphorus diet (Nx-phosphorus)
(1.2% phosphorus and 0.6% calcium) (Purina Mills). To
ensure equal caloric intake, all intact-control (N = 15)
animals were pair-fed with Nx animals by providing the
amount of food each day to intact-control rats that had
been consumed the previous day by Nx animals. A group
of sham-Nx animals (intact-ad libitum) (N = 15) were fed
ad libitum with the standard rodent chow. Another group
of animals with normal renal function given high phos-
phorus diet was not included in the current experiment.
To evaluate longitudinal bone growth, the animals were
given intraperitoneal injections of oxytetracycline hy-
drochloride, 1 mg/kg/dose, 3 days and 1 day prior to sacri-
fice. Four weeks after the second-stage nephrectomy, the
animals were randomly divided into two groups. In group
I, animals from the Nx-control (N = 3), Nx-phosphorus
(N = 5), intact-control (N = 10), and intact-ad libitum
(N = 10) groups were anesthetized, killed by exsanguina-
tion by cardiac puncture, and underwent transcardiac per-
fusion with 4% paraformaldehyde in phosphate-buffered
saline (PBS). The tibiae were decalcified for 2 weeks and
embedded in paraffin as previously described [2]. Five
micrometer sections of bone were obtained for morpho-
metric analysis, in situ hybridization, and immunohisto-
chemistry experiments.
In group II, the remaining animals, Nx-control
(N = 3), Nx-phosphorus (N = 5), intact-control (N = 5),
and intact-ad libitum (N = 5), were given lethal doses of
pentobarbital (300 mg/kg intraperitoneally). The growth
plate in the proximal tibia of the left leg was quickly col-
lected to measure the rate of elongation. For each of
the growth plate, two thin slabs were cut and were ob-
served under epifluorescence microscopy with an exci-
tation filter of 330 to 380 nm and a barrier filter of 420
nm. To estimate bone elongation over 48 hours, the dis-
tance between the leading edges of the two fluorescent
bands was measured four times using an ocular reticle
and the average measurement was converted to elonga-
tion for 24 hours [7]. When there is only one label discern-
able, the measured distance between the visible label and
the chondro-osseous junction is then used for calculation
of bone elongation. For optimal fixation, the remaining
growth plate was fixed in 2% glutaraldehyde in 0.05 mol/L
cacodylate buffer (pH 7.35) with 0.7% ruthenium hex-
amine trichloride and embedded in Epon-araldite [8,
9], and sections were obtained for histology. The right
tibia was also collected, freed of adherent tissue, fixed
in 4% parafolmaldehyde in PBS for 24 hours, decalci-
fied in 15% ethylenediaminetetraacetic acid (EDTA) in
paraformaldehyde for approximately 2 weeks and pro-
cessed together with group I as described above. All
animals were included in all in situ hybridization and im-
munohistochemistry experiments, Nx-control (N = 6),
Nx-phosphorus (N = 10), intact-control (N = 15), and
intact-ad libitum (N = 15).
Serum biochemical determinations
Serum was obtained by centrifugation, and samples
were stored at −70◦C. Serum urea nitrogen, creatinine,
calcium, and phosphorus levels were measured using
standard laboratory methods. Serum intact PTH levels
were measured using the Rat Intact PTH enzyme-linked
immunosorbent assay (ELISA) Kit (Immutopics, Inc.,
San Clemente, CA, USA).
Growth plate morphometry
For morphometric analysis, three 5 lm sections of bone
were obtained from each tibia, stained with hematoxylin
and eosin, viewed by light microscopy at 20× and images
were captured onto a computer monitor. The total width
of the growth plate and the widths of the proliferative
and hypertrophic zones were measured using an image
analysis software (Elektronik 200) (Kontron Instruments,
Ltd., Hallbergmoos, Germany) as previously described
[2].
In situ hybridization (radioactive and nonradioactive)
In situ hybridization was performed using methods de-
scribed elsewhere [2, 10]. 35S-labeled sense and antisense
riboprobes encoding mouse matrix metalloproteinase-
9 (MMP-9)/gelatinase B and rat vascular endothelial
growth factor were labeled to a specific activity of 1 to 2
1742 Sanchez et al: Growth plate alterations in renal failure
× 109 cpm/lg. After hybridization and posthybridization
washing, the slides were exposed to x-ray film overnight,
and emulsion autoradiography was done using NTB-2
(Eastman Kodak, Rochester, New York) at 4◦C.
For nonradioactive in situ hybridization, probes encod-
ing histone-4, mouse type X collagen, rat PTH/PTHrP
receptor, and IGF-I receptor were linearized, purified,
labeled with digoxigenin-uridine triphosphate (UTP)
in the nucleotide-triphosphate (NTP) labeling mixture
(Roche Diagnostics, Mannheim, Germany), and mixed
in a hybridization mixture [11]. The specimens were hy-
bridized with specific riboprobes at 100 lL/specimen at
55◦C to 60◦C in a humidified chamber overnight. Fol-
lowing the overnight hybridization, the specimens were
washed, incubated with the secondary antibody, and color
was developed [11].
Quantification of in situ hybridization signals
For the specimens hybridized with 35S, the slides were
viewed at 100× by bright field microscopy and the num-
ber of silver grains overlying each chondrocyte profile
was counted using an image analysis system [2]. Data are
expressed as the number of silver grains/1000 lm2 of cell
profile. For the nonradioactive in situ hybridization and
immunohistochemistry experiments, the number of cells
expressing the specific mRNA or protein was counted and
expressed as percentage of the number of positive cells to
the total number of cells in the appropriate growth plate
zone where the mRNA expression is localized [11]. The
mRNA expression for MMP-9/gelatinase B was quan-
tified by measuring the area with positive staining and
results are expressed as labeled area over the total tissue
area in the chondro-osseous junction [11].
Immunohistochemistry [Bcl-2, Bax, IGF-I protein,
IGF binding protein-3, proliferating cell nuclear
antigen (PCNA), terminal deoxynucleotidyl
transferase-mediated uridine triphosphate nick end
labeling (TUNEL) assay, tartrate-resistant acid
phosphatase (TRAP)]
Immunohistochemistry was performed using methods
described previously using the following primary anti-
bodies: monoclonal Bcl-2 antibody (Santa Cruz Biotech-
nology, San Diego, CA, USA), monoclonal Bax antibody
(Santa Cruz Biotechnology), monoclonal IGF-I pro-
tein antibody (Upstate Biotechnology, Lake Placid, NY,
USA), and polyclonal IGF binding protein-3 antibody
(Santa Cruz Biotechnology) [11].
For PCNA, the tissues were immunostained with the
mouse anti-PCNA antibody (Zymed Laboratories, South
San Francisco, CA, USA). For the TUNEL assay, the
specimens were labeled using the kit from Intergen
(Gaithersburg, MD, USA). The number of TUNEL-
positive cells were counted and expressed as percent-
Table 1. Anthropomorphic and tibial length measurements in all
groups
Nx- Nx- Intact- Intact-ad
control phosphorus control libitum
N = 6 N = 10 Nx = 15 N = 15
Gain in weighta g 100 ± 29c 100 ± 34c 126 ± 21 217 ± 25d
Gain in lengtha cm 11 ± 1.7c 10 ± 2.2c 13 ± 1.3 17 ± 0.9d
Tibial lengthb cm 3.5 ± 0.1c 3.4 ± 0.1c 3.8 ± 0.1 4.0 ± 0.1d
Nx is nephrectomized.
aDifference in weight or length between baseline and at the end of the
4-week study period; bObtained at the end of the study period; cP < 0.0001 vs.
intact-control; dP < 0.0001 vs. intact-control, Nx-control, and Nx-phosphorus.
age of the total number of terminal chondrocytes in each
section. Histochemical staining for TRAP was done us-
ing methods reported previously [2]. Image analysis was
done in tissue sections viewed at 50× and the number of
TRAP-positive cells in the chondro-osseous junction was
quantified and expressed as number of cells per area mea-
sured in the chondro-osseous junction and in the nearby
primary spongiosa.
Statistical analysis
All results are expressed as mean values ± 1 SD.
Data were evaluated by one-way analysis fo variance
(ANOVA) and comparisons among groups were done us-
ing Bonferroni/Dunn post hoc tests using the StatView
statistical software (SAS Institute, Cary, NC, USA). For
all statistical tests, probability values less than 5% were
considered to be significant.
RESULTS
Compared to our previous experiments, there was a
significant increase in mortality rate from 5% to 10% in
our earlier studies [2, 12] to approximately 25% in the
current set of experiments. The rats used in this study
were much younger with body weights between 50 to 60
g compared to 60 to 80 g in our previous studies. Most
of the mortality occurred within 7 days after the second-
stage surgery.
Anthromorphic measurements
As expected, the mean gain in body weight was twofold
greater in the intact-ad libitum animals compared to the
intact-control, Nx-phosphorus, and Nx-control groups
(Table 1). There was a 35% and 15% increase in total
body length at the end of the study period in the intact-
ad libitum and intact-control groups (Table 1). Similarly,
tibial length measurements were much longer by approx-
imately 11% to 15% in the animals with normal renal
function compared to the Nx animals (Table 1). Tibial
length and gain in body length at the end of the study
period did not differ between the two Nx groups; such
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Table 2. Serum biochemical parameters in all groups obtained at the
end of the study period
Nx- Nx- Intact- Intact-ad
control phosphorus control libitum
N = 6 N = 10 N = 15 N = 15
Parathyroid 323 ± 206b 1038 ± 633a 120 ± 53 75 ± 46
hormone
pg/mL
Calcium 9.2 ± 1.6 7.3 ± 0.7a 10 ± 1.3 10 ± 1.4
mg/dL
Phosphorus 11 ± 1.3 16 ± 5.0a 10 ± 2.3 11 ± 1.5
mg/dL
Urea nitrogen 100 ± 25b 81 ± 11b 16 ± 2 22 ± 3
mg/dL
Creatinine 1.0 ± 0.4b 0.7 ± 0.1b 0.3 ± 0.08 0.3 ± 0.07
mg/dL
Nx is nephrectomized.
aP < 0.001 vs. Nx-control, intact-control, and intact-ad libitum; bP < 0.05 vs.
intact-control and intact-ad libitum.
findings may be due in part to the mildly elevated mean
serum creatinine level in the Nx-control animals (1.0 ±
0.1 mg/dL) compared to the phosphorus-loaded group
(0.7 ± 0.1 mg/dL). Serum creatinine levels moderately
correlated with tibial length and body length measure-
ments in the current study (R= −0.7, P < 0.001).
Serum urea nitrogen and serum creatinine levels were
higher in the Nx animals (Table 2). Serum phospho-
rus levels rose and serum calcium levels declined in the
Nx animals given high phosphorus diet (Nx-phosphorus)
(Table 2). Intact PTH levels increased eightfold in the
Nx-phosphorus animals and were modestly elevated in
the Nx-control animals compared to the groups with in-
tact renal function (Table 2). Serum PTH levels corre-
lated with measurements of tibial length (R = −0.7, P <
0.001), gain in body length (R = −0.6, P < 0.001), and
TRAP staining (R = 0.6, P < 0.05).
The total thickness of the growth plate was wider by ap-
proximately 35% in the intact-ad libitum animals when
compared to the intact-control and Nx-control groups
(369 ± 29 lm versus 323 ± 50 lm and 335 ± 57 lm,
respectively) (P < 0.007) (Fig. 1). In contrast, there was
a significant reduction in the width of the growth plate
in the Nx-phosphorus animals (288 ± 42 lm) (P < 0.04)
(Fig. 1). As previously demonstrated in our earlier ex-
periments, alterations in the architecture of the growth
plate cartilage were evident mainly in the animals given
high phosphorus diet with the loss of the columnar orga-
nization of the proliferating chondrocytes [2] (Fig. 1). The
area occupied by the proliferating chondrocytes in the Nx
animals decreased by approximately 20% compared to
the groups with normal renal function (Fig. 1) (0.5 ± 0.04
versus 0.6 ± 0.04, respectively) (P < 0.02). In addition,
the area occupied by the hypertrophic chondrocytes de-
creased by 11% in the phosphorus-loaded animals (0.40
± 0.03 versus 0.46 ± 0.03, 0.45 ± 0.02, and 0.45 ± 0.03,
respectively) (P < 0.001), in Nx-control, intact-control,
and intact-ad libitum groups (Fig. 1).
There was a mild reduction in double tetracycline la-
beling in the phosphorus-loaded nephrectomized animals
(Nx-phosphorus), 122 ± 22 lm/day, compared to Nx-
control, intact-control, and intact-ad libitum groups, re-
spectively (212 ± 73, 178 ± 42, and 196 ± 25 lm/day),
but these values did not reach statistical significance
(P < 0.06). These findings reflect the lack of difference
in tibial length and body length measurements at the end
of the study period between the two Nx groups. It is un-
clear why the tetracycline label did not differ between
the Nx animals and those with normal renal function. A
possible explanation may be the limitation of the tech-
nique used in the current study, particularly the method
of tetracycline administration and the system of measure-
ment between the two labels. There may be a wide vari-
ability in the amount of tetracycline absorbed using the
intraperitoneal method of injection such that some an-
imals may not demonstrate a clear separation between
the two tetracycline labels.
IGF-I protein staining significantly declined by 24%
in the Nx-phosphorus animals (P < 0.01), compared to
intact-control and intact-ad libitum groups. In the Nx-
control group, IGF-I protein expression decreased by
15% (P = 0.02 (Fig. 2). IGF-binding proteins (IGFBP)-
3 protein expression declined by approximately 39% in
the Nx animals compared to the groups with normal renal
function (P < 0.04) (Fig. 3). In contrast, IGF-I receptor
mRNA expression did not differ among groups. IGF-I
protein expression correlated with the measurements of
body length (R = 0.6, P < 0.01) and with PTH/PTHrP
receptor (R = 0.8, P < 0.01).
There was a 30% reduction in PTH/PTHrP receptor
mRNA transcripts (Fig. 4) and at least a twofold in-
crease in the histochemical staining for TRAP in the
phosphorus-loaded animals (0.005 ± 0.002 cells per area
in Nx-phosphorus group compared to 0.002 ± 0.001 cells
per area in Nx-control, intact-control and intact-ad libi-
tum animals) (P < 0.02). Despite changes in PTH/PTHrP
receptor, the protein expression for Indian hedgehog did
not change. The PTH/PTHrP receptor expression corre-
lated with serum PTH levels measured using the intact
assay (R = −0.8, P < 0.001).
Markers used to evaluate chondrocyte proliferation,
including PCNA and histone-4 mRNA expression de-
clined in both Nx groups; PCNA staining was 0.4 ± 0.1
and 0.5 ± 0.07 in Nx-phosphorus and Nx-control groups
versus 0.61 ± 0.06 in intact-control and intact-ad libitum
animals (P < 0.001), and histone-4 mRNA expression,
0.60 ± 0.04 in both Nx groups and 0.74 ± 0.07 in ani-
mals with normal renal function (P < 0.02). On the other
hand, the expression of type II collagen, type X colla-
gen, gelatinase B, Bcl-2 protein, Bax protein, and vascu-
lar endothelial growth factor did not differ in all groups.
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Fig. 1. Measurements of the total width of
the growth plate () and the width of
the area occupied by the proliferating and
() and hypertrophic chondrocytes ( ) are
demonstrated. (Upper panel) aP < 0.04 vs.
nephrectomized (Nx)-control, intact-control,
and intact-ad libitum groups; bP < 0.007 vs.
intact-control and intact-ad libitum animals;
cP < 0.03 vs, Nx-control, intact-control, and
intact-ad libitum; dP < 0.007 vs. Nx-control
and intact-control. The middle panel denotes
the morphology of the growth plate opti-
mally fixed in Ruthenium Hexamine Trichlo-
ride (20×). Note that there is distortion of the
growth plate architecture in the phosphorus
loaded animals (second panel), including the
loss of columnar organization of the chondro-
cytes and changes in the growth plate matrix.
(Lower panel) The low magnification of the
growth plate (14×), including parts of the pri-
mary spongiosa.
The number of apoptotic terminal chondrocytes in the
chondro-osseous junction remained unchanged in both
Nx groups and in animals with normal renal function.
DISCUSSION
Impairment of linear growth in renal failure has been
attributed to several factors, including tissue resistance to
the actions of growth hormone partly due to a decrease
in growth hormone receptor expression, low hepatic
expression of IGF-I mRNA, and diminished bioactiv-
ity of IGF-I–dependent growth processes [13, 14]. In our
current study, the reduction in IGF-I protein expression
was much greater in rats with advanced secondary hyper-
parathyroidism compared to the animals with mild ele-
vations in PTH levels. Although the severity of growth
impairment was equivalent in both groups of Nx animals,
the width of the growth plate cartilage was much nar-
rower in the phosphorus-loaded animals and this reduc-
tion may lead to further reduction in longitudinal growth
as the animals matures. Serum IGF-I levels were not ob-
tained in the current study, but Tonshoff et al [13] have
reported that although the plasma levels of IGF-I did not
differ between animals with renal failure and normal re-
nal function, there was an associated reduction in IGF-I
mRNA expression in the liver, lung, and muscle of the
uremic animals. Thus, serum levels of IGF-I may not be
an important determinant of IGF-I mRNA expression in
the presence of renal failure. Despite equivalent caloric
intake, the Nx animals had significantly less weight gain
and shorter body and tibial lengths at the end of the 4-
week study period when compared to the control animals.
There was no difference demonstrated between the tibial
length and body length measurements between the Nx-
control and Nx-phosphorus groups. These findings may
suggest that the slightly higher serum creatinine in the
Nx-control animals may have affected growth indepen-
dent of the degree of secondary hyperparathyroidism.
IGF-I participates in longitudinal growth by partly en-
hancing chondrocyte proliferation, amplifying chondro-
cyte hypertrophy and increasing matrix production [15].
In the IGF-I null mice, longitudinal growth declined by
35% primarily due to the smaller size of the chondrocytes
occupying the hypertrophic zone without any associated
impairment in the expression of specialized proteins, in-
cluding type X collagen and alkaline phosphatase [15]. In
our current and previous experiments, alterations in the
histology of the growth plate in rats with renal failure and
advanced secondary hyperparathyroidism were not asso-
ciated with changes in the expression of type II collagen
and type X collagen in the proliferating and hypertrophic
chondrocytes.
In various clinical and animal studies, the administra-
tion of growth hormone, IGF-I or both have led to an
increase in linear growth in children with chronic re-
nal failure, augmented bone growth, and even enhanced
IGF-I expression in the growth plate of uremic rats [4,
16, 17]. To stimulate growth in children, supraphysiologic
doses of recombinant human growth hormone (rhGH)
are given in order to increase circulating IGF-I levels
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Fig. 2. Immunohistochemical localization of
insulin-like growth factor-I (IGF-I) protein
staining (denoted by brown color) in the
lower proliferative zone and in the hyper-
trophic chondrocytes (50×). aP < 0.01 vs.
nephrectomized (Nx)-control, intact-control,
and intact-ad libitum groups; bP < 0.02 vs. an-
imals with normal renal function.
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Fig. 3. Quantification of the insulin-like
growth factor binding protein-3 (IGFBP-3)
signals. (Upper panel) aP < 0.04 vs. intact-
control and intact-ad ibitum animals. (Lower
panel) The localization of IGFBP-3 in the
growth plate (brown color) (50×).
and counteract the effects of the accumulated IGFBP,
especially IGFBP-3. Previous studies have shown that
the growth response to rhGH therapy was much bet-
ter in children with chronic renal failure on conservative
management compared to children undergoing dialysis
[18]; such findings may be attributed to the possibility
that there is a greater insensitivity to growth hormone
therapy in dialysis patients mediated in part by the lower
IGF-I protein expression in the growth plate cartilage.
Our current findings show that IGF-I protein expression
was much less in rats with advanced secondary hyper-
parathyroidism compared to animals with mild secondary
hyperparathyroidism, and these changes were accompa-
nied by a decrease in PTH/PTHrP receptor mRNA. The
decline in IGF-I protein without any changes in IGF-I
receptor expression as demonstrated in the current study
may suggest the presence of postreceptor signaling defect
that occur in the presence of renal failure and secondary
hyperparathyroidism.
PTHrP is an autocrine/paracrine factor that has a va-
riety of physiologic functions and expressed in various
tissues including the skeleton. In the growth plate car-
tilage, PTHrP and Indian hedgehog are responsible, at
least in part, for the control of chondrocyte prolifera-
tion and chondrocyte differentiation [19, 20]. The growth
plate cartilage was much smaller in the rats with ad-
vanced secondary hyperparathyroidism mainly due to the
smaller proportion of the chondrocytes in the prolifera-
tive and hypertrophic zones. In contrast to other reports,
we did not demonstrate a decrease in the width of the
hypertrophic zone in Nx animals with mild secondary
hyperparathyroidism and there were no changes in the
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Fig. 4. Parathyroid hormone/parathyroid
hormone receptor protein (PTH/PTHrP)
receptor mRNA expression in the lower
proliferative and upper hypertrophic zones
(denoted by black color) in all groups,
including the quantification of the mRNA
transcripts. (Upper panel) aP < 0.001 vs.
nephrectomized (Nx)-control, intact-control,
and intact-ad libitum groups (50×).
expression of both type X collagen and type II col-
lagen. The shorter proliferative zone in the rats with
advanced secondary hyperparathyroidism may be partly
explained by the low expression of PTH/PTHrP receptor
mRNA. Several investigators have demonstrated that the
layers of proliferating chondrocytes are mainly affected
by PTHrP signaling such that the growth plate of PTHrP
(−/−) null mice was 30% shorter than the wild-type and
almost completely absent in the PTH/PTHrP receptor
(−/−) mice [21–23]. Chondrocyte differentiation is con-
trolled at various steps by both PTHrP and Ihh through
PTH/PTHrP and Patched 1 receptors [24, 25]. In the cur-
rent set of experiments, the expression of Ihh protein
did not differ between the Nx groups and the animals
with normal renal function despite a significant decline
in PTH/PTHrP receptor expression in the phosphorus-
loaded animals; such findings may suggest a dysregulation
in the PTH/PTHrP-Ihh signaling pathway in the pres-
ence of advanced secondary hyperparathyroidism. The
expression of Patched 1 receptor was not evaluated in the
current experiments. The determination of bone growth
and bone elongation is partly dependent on the number
of hypertrophic and proliferating chondrocytes available
in the growth plate, and the interaction among multiple
regulators and their receptors. The interactions of these
regulators may be altered in the presence of renal failure
and advanced secondary hyperparathyroidism.
A dramatic increase in aggrecan synthesis in chon-
drocytes isolated from rib cages of rat embryos was
demonstrated after treatment with PTH-(1–34) [26].
Proteoglycan synthesis was not evaluated in the current
study; however, a decrease in the production of aggre-
can may contribute to the shorter growth evident in rats
with advanced secondary hyperparathyroidism. Alter-
ations in the growth plate architecture are evident in the
current study, including changes in the matrix and the
loss of columnar organization of the chondrocytes (see
Fig. 1). Although, there was a significant elevation of
the serum PTH levels in the current study particularly
in the phosphorus-loaded rats, the increase may be due
to the presence of the biologically inactive C-terminal
component of PTH that may actually inhibit not only
chondrocyte proliferative activity but also the synthe-
sis of proteoglycans. The PTH assay used in our study
measured both the intact PTH-(1–84) and the PTH C-
terminal fragment (39–84). PTH C-terminal (7–84) frag-
ments have been reported to inhibit the calcemic actions
of hPTH-(1–34) or hPTH-(1–84) in parathyroidec-
tomized rats and exert a direct anti-resorptive effect on
neonatal mouse calvarial bone independent of the type
I PTH receptor [27, 28]. Harvey et al [26] reported that
only the administration of N-terminally intact PTH and
PTHrP were effective in both promoting synthesis and
incorporation of aggrecan into the cell and extracellu-
lar matrix in the rat costal chondrocytes. These findings
may explain the lack of differences in the expression of
type X collagen and type II collagen particularly in the
hypertrophic chondrocytes of Nx animals in the current
experiment.
The PTH-stimulated aggrecan synthesis has been re-
ported to be dependent on the IGF-I/IGF binding pro-
tein axis since the addition of a neutralizing antibody to
IGF-I during PTH treatment resulted in the inhibition
of aggrecan synthesis [26]. In addition, Bikle et al [29]
have reported that the anabolic effects of PTH in bone
did not occur in the absence of IGF-I. Since IGF-I has
been postulated to mediate the anabolic actions of PTH
on the bone, the significantly lower expression of IGF-I
in the current set of experiments, may at least in part con-
tribute to the impairment of growth in renal failure. The
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down-regulation of PTH/PTHrP receptor transcripts and
the increase staining for chondroclast/osteoclast activity
in the chondro-osseous junction may further worsen the
growth retardation in these animals by increasing carti-
lage/bone resorption without any increase in chondrocyte
proliferation or chondrocyte turnover.
IGFBP-3 protein expression decreased in both groups
of rats with renal failure. The biologic activity of IGFBP-3
is complex. Under preincubation conditions with IGF-I,
IGFBP-3 enhanced IGF-I responsiveness by facilitating
IGF-I cell surface binding, whereas IGFBP-3 under co-
incubation conditions with IGF-I, exerted an antipro-
liferative and inhibitory effect [30]. In our study, the
low IGFBP-3 protein expression was certainly associated
with decreased IGF-I protein staining despite compara-
ble expression of IGF-I receptor in the animals with intact
renal function and rats with renal failure.
Overall, the impairment of growth evident in rats with
renal failure and mild secondary hyperparathyroidism
may, in part be due to the mild decrease in IGF-I activ-
ity and lower IGFBP-3 expression. In rats with advanced
secondary hyperparathyroidism, however, the decline in
PTH/PTHrP receptor mRNA expression and further de-
crease in IGF-I protein staining may worsen bone growth
in these animals despite higher levels of serum PTH and
comparable caloric intake. These findings have important
implications in the therapeutic armamentarium currently
available to enhance linear growth in young children with
chronic renal failure. Supraphysiologic doses of rhGH
have been demonstrated to increase height in children
with chronic renal failure [31], but the growth response
in dialysis patients is suboptimal [18]. Possible explana-
tions for the blunted growth response in dialysis patients
include the use of higher doses of vitamin D especially
calcitriol required to control secondary hyperparathy-
roidism. When administered in high doses, calcitriol in-
hibits chondrocyte proliferation probably through its
actions on IGF-I and IGFBP-4 [32, 33]. Growth hor-
mone therapy, however, is not without its problems since
worsening of secondary hyperparathyroidism has been
reported in children undergoing dialysis therapy [34][ab-
stract; Kuizon BD et al, J Am Soc Nephrol 11:577A,
2000]. On the other hand, the administration of IGF-I
has been shown to increase height velocity when given
to children with growth hormone insensitivity syndrome
and improved growth in uremic animals, but the growth
response is not comparable to growth hormone [35]. In
the long run, exogenous IGF-I administration may sup-
press endogenous growth hormone production and the
reported metabolic complications associated with IGF-
I, particularly hypoglycemia may not be well tolerated
in children [35]. Further studies are required to evalu-
ate the safety and efficacy of IGF-I therapy in children
with chronic renal failure. Future development of ther-
apeutic agents that can selectively enhance local IGF-
I expression and increase PTH/PTHrP receptor in the
growth plate cartilage may be helpful in the improve-
ment of growth in children with chronic renal failure and
secondary hyperparathyroidism.
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